DOCSLIB.ORG

马丁代尔药物大典38th 01__2027.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
马丁代尔药物大典38th 01__2027.Pdf 1186 Bone Lasofoxifene Ta rtrate (BANM, USAN r/NNM) 0 Minodronate Profile CP-336156(8: Lasofoxifene, Tartrate de; Lasofoxifeni Tartras; Odanacatib is a cathepsin-K inhibitor that reduces bone TartriHo de lasofoxifeno; f!a3o¢oKc'1$eHa TaprpaT: Minodronic Acid (r/NN) resorption. It is being investigated for the treatment of (+c;;;-5,6,7,1;cJetra hydro-6-pheny!-5.-{pc[2-.(1 -pyrrglidinyi) osteoporosis. Acide Mlnodronicjue; 1\cido minQdr6nlco; . Acidum minqc ethmy]pheny!�2-napht�ol Q-tartrate (1:1 ). •. References. 2 2 MwHo/!po�oBaR I. Bone HG, et a!. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a c,,H,,N0:/:4H<>O,�S61,6 011()-59 0; YH-5 9; • YM"S29; ••.• �����:aT ;·_. study in postmenopausal women with low bone density. J CAS--· 790l9 1 -29�R Res 2009; 25: 937---47. ( 1 ·Hydroxy•2•imipazo[1 ,2:a]pyridin-3-ylethyiidene)dipho- ATC G03Xt03 . · 2. Lewiecki EM. Odanacatib, a cathepsin K inhibitor for the treatment of sphonicacid. · . osteoporosis and other skeletal disorders associated with excessive bone C9 H,2N2G.h,•3;1.4:.1 remodeling. !Drugs 2009; 12: 799-809. UNII (45 � 12765J'4Jo5 NOTE. The name Fablyn has been used as a trade mark lor UNIJ �·40SG.R63TGt lasofoxifene tartrate. Oxidronate Profile Profile Minodronate is a bisphosphonate that inhibits bone Lasofoxifene is a selective oestrogen receptor modulator resorption. It is given as minodronic acid hydrate for the similar to raloxifene (p. 2303.1 ), that was developed lor the treatment of osteoporosis; l mg is given orally once daily, treatment of osteoporosis in postmenopausal women at usually in the morning. Specific instructions for oral use increased risk of fracture. (see Precautions in Alendronate, p. ll72.3) should be References. followed to minimise adverse effects and permit adequate 1. Gennari L. Lasofoxifene, a new selective estrogen receptor modulator for absorption. the treatment of osteoporosis and vaginal atrophy. Expert Opin Pharmacother 2009; 10: 2209-20. 2. Cummings SR, et al. PEARL Study Investigators. Lasofoxifene in P epa a ons .........................r r ti ...... ........... ....... ..... .......... postmenopausal women with osteoporosis. N Eng! J Med 2010; 362: 686- . ..... .. 96. Proprietary Preparations (details are given in Volume B) 3. LaCroix AZ, et al. PEARL Investigators. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic Single-ingredient Prepara6ons, Jpn: Bonoteo: Recalbon. women. J Natl Cancer Inst 2010; 102: 1706-15. 4. Ensrud K, et al. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: five-year results from the postmenopausal evaluation and risk reduction with lasofoxifene Neridronate (PEARL) trial. Circulation 2010; 122: 1716-24. 5. Goldstein SR, et al. Postmenopausal evaluation and risk reduction with lasofoxifene (PEARL) trial: 5-year gynecological outcomes. Menopause Neridronic Acid (r/NN) 2011; 18: 17-22. 6. Peterson GM, et a/. Lasofoxifene: selective estrogen receptor modulator Acide Nerldror\ique; Acido nertdr6nit'o; Aci<lum .neridronl' for the prevention and treatment of postmenopausal osteoporosis. Ann corp; AHDP';. AHHexBP;. Arninohexane DiphosphonJt!:'; Pharmacother 2011; 45: 499-509. ·. Nerid\6nico; addo; Hep.>IIJPoHoBaf! Kv.cpota. (6-Amino-l-hydroxyhexylid�ne)diphosphonic acfid. Oxidronate is a bisphosphonate with general properties C.HpNQ.,P2;:277.1 similar to those of the other bisphosphonates (p. 1173.3). It Medronate has a strong affinity for bone. A chelate of oxidronate C;l$ = 79778-41-9. disodium with radioactive technetium-99m (p. 2228.1) is UNII �BU27fJ3RIN4. used diagnostically as a bone scanning agent; it is given Medronic Acid {BAN, USAN, piNNJ intravenously. NeridronateSo dium (r/NNM) A<:id rnedronique;Actde Medronlque; Acido medr6n(co; Acidurn medronlcurn; Medrt)nico, acido; Mel!pm;oBaR Natrii . Neridronas: Nerldronate •·· .· · sodico; HaTP11n Hep1-1iJpohaT. UNit -H6:!VB49QOF. Profile Neridronate is an aminobisphdsphonate with Pharmacopoeias. In Bur. (see p. vii). properties to those of the bisphosphonates in general Ph. Eur. 8: (Medronic Add for Radiopharmaceutical (p. 1173.3). It inhibits bone resorption and is given Preparations). A white or almost white, amorphous or intravenously as the sodium salt in the management of crystalline, hygroscopic powder. Very soluble in water; very osteogenesis imperlecta (p. ll67.3); it has been used in the slightly soluble in absolute alcohol; practically insoluble in treatment of malignant hypercalcaemia (p. 1167.2) and dichlormnethane. Store in airtight containers. Protect from diseases associated with excessive bone turnover such as light. Paget's disease of bone (p. 1169.3) and osteoporosis (p. ll68.l). The intramuscular route has also been used. Medronate Disodium (USAN, piNNMJ References, 1. O'Rourke NP, et al. Treatment of malignant hypercalcaemia with Disodium Medmf)ate (BANIVIJ; Disodiurn Methylene.Dipho­ aminohexane bisphosphonate (neridronate). Br J Cancer 1994; 69: 914- 17. sphonate; MDP; Medronas Dinatticurn; M�dronat� Dis­ odique: Medronato ar 2. Filipponi P, et at. Paget's disease of bone: benefits of neridronate as a first dls6dico; ,£l1<1H p11i'1 Me,!lpaHar. treatment and in cases of relap!>e after dodronate. Bone 1998; 23: 543-8. Disodiurn d.ihydrogen methylenedip�osphonate. 3. Adami S, et al. Short-term intravenous therapy with neridronate in CH4Na,00P2=2200 Paget's disease. Clin Exp Rheumatol 2002; 20: 55-8. 2568 1 -89'4. 4. Adami S, et al. Intravenous neridronate in adults with osteogenesis CAS ,;...:• 18: imperfecta. 1 Bone Miner Res 2003; 126-30. UN)( ....,.· HAY5MT18L3. 5. Braga V, et al. Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis. Bone 2003; 33: 342-5. 6. Cascella T, et al. Effects of neridronate treatment in elderly women with Profile osteoporosis. J Endocrinol Invest 2005; 28: 202-8. 7. Gatti D, et a!. Intravenous neridronate in children with osteogenesis Medronate is a bisphosphonate with general properties imperfecta: a randomized controlled study. J Bone Miner Res 2005; 20: similar to those of the other bisphosphonates (p. 1173.3 ). It 758-63. 8. Adami S, et al. Intramuscular neridronate in postmenopausal women has a strong affinity for bone. Complexes of medronate with low bone mineral density. Calci[ Tissue Int 2008; 83: 301-7. disodium and stannous chloride or fluoride, or medronic 9. Benucd M, et al. Effects of monthly intramuscular neridronate in acid, stannous chloride dihydrate, and ascorbic acid, are rheumatic patients in chronic treatment with low-dose glucocorticoids. labelled with radioactive technetium-99m (p. 2228.1) and Clin Exp Rheumatol 2009; 27: 567-73. used diagnostically as bone scanning agents; they are given intravenously. Preparations . ....................... Proprietary Preparations (details are given in Volume B) Hypersensitivity. For reference to a severe allergic reaction attributed to the medronate component of a radiopharma­ Single-ingredient Preparations. Ital.: Nerixia. ceutical, see under Adverse Effects and Precautions of Bis­ phosphonates, p. 1177.1. Odanacatib (USAN, riNNI bdahacarlbllm: OAaHaKaTH6. _ 'Cjianocy�lop;opyl)4f)ooro-4-rnethyl,2-(!i Proprietary Preparations (details are given in Volume B) (25)-N-(1 1 5}c2,2,2" Ph. Eur. 8: (Pamidronate Disodium Pentahydrate). A white trifiuoro-1_-[4' -(rne'!hyl�ulfdny!)(i,1 '-btpherwll-4.'yl]ethyl} · or almost white, crystalline powder. Soluble in water; Single-ingredient Preparations. Denm.: Amerscan Medronatet; amlno)pent� narnipe. practically insoluble in dichloromethane. It is sparingly Irl. : Medronate Draximaget; Israel: Frosstimage Kit (MDP). C2sH21F.l\t,035=525.6 soluble in dilute mineral adds and dissolves in dilute Multi-ingredient Preparations. Denm.: Amerscan Stannoust. C45 -'--' 603139- i9"i alkaline solutions. A 1.0% solution in water has a pH of 7.8 UN/I � N673F6W2 vN. to 8.8. All cross-references refer to entries in Volume A .
Load more

Recommended publications
  • Protocol Supplementary
    Optimal Pharmacological Management and Prevention of Glucocorticoid-Induced Osteoporosis (GIOP) Protocol for a Systematic Review and Network Meta-Analysis Supplementary Materials: Sample Search Strategy Supplementary 1: MEDLINE Search Strategy Database: OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present Line 1 exp Osteoporosis/ 2 osteoporos?s.ti,ab,kf. 3 Bone Diseases, Metabolic/ 4 osteop?eni*.ti,ab,kf. 5 Bone Diseases/ 6 exp Bone Resorption/ 7 malabsorption.ti,ab,kf. 8 Bone Density/ 9 BMD.ti,ab,kf. 10 exp Fractures, Bone/ 11 fracture*.ti,ab,kf. 12 (bone* adj2 (loss* or disease* or resorption* or densit* or content* or fragil* or mass* or demineral* or decalcif* or calcif* or strength*)).ti,ab,kf. 13 osteomalacia.ti,ab,kf. 14 or/1-13 15 exp Glucocorticoids/ 16 exp Steroids/ 17 (glucocorticoid* or steroid* or prednisone or prednisolone or hydrocortisone or cortisone or triamcinolone or dexamethasone or betamethasone or methylprednisolone).ti,ab,kf. 18 or/15-17 19 14 and 18 20 ((glucocorticoid-induced or glucosteroid-induced or corticosteroid-induced or glucocorticosteroid-induced) adj1 osteoporos?s).ti,ab,kf. 21 19 or 20 22 exp Diphosphonates/ 23 (bisphosphon* or diphosphon*).ti,ab,kf. 24 exp organophosphates/ or organophosphonates/ 25 (organophosphate* or organophosphonate*).ti,ab,kf. 26 (alendronate or alendronic acid or Fosamax or Binosto or Denfos or Fosagen or Lendrate).ti,ab,kf. 27 (Densidron or Adrovance or Alenotop or Alned or Dronat or Durost or Fixopan or Forosa or Fosval or Huesobone or Ostemax or Oseolen or Arendal or Beenos or Berlex or Fosalen or Fosmin or Fostolin or Fosavance).ti,ab,kf.
    [Show full text]
  • Msx-1 Is Suppressed in Bisphosphonate Exposed Jaw Bone
    Msx-1 is suppressed in Bisphosphonate exposed jaw bone- analysis of bone turnover related cell signalling Falk Wehrhan, Peter Hyckel, Kerstin Amann, Jutta Ries, Philipp Stockmann, Karl Andreas Schlegel, Friedrich Wilhelm Neukam, Emeka Nkenke To cite this version: Falk Wehrhan, Peter Hyckel, Kerstin Amann, Jutta Ries, Philipp Stockmann, et al.. Msx-1 is sup- pressed in Bisphosphonate exposed jaw bone- analysis of bone turnover related cell signalling. Oral Diseases, Wiley, 2011, 17 (4), pp.433. 10.1111/j.1601-0825.2010.01778.x. hal-00618503 HAL Id: hal-00618503 https://hal.archives-ouvertes.fr/hal-00618503 Submitted on 2 Sep 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Oral Diseases - Manuscript Copy Oral Diseases - Manuscript Copy Msx-1 is suppressed in Bisphosphonate exposed jaw bone- analysis of bone turnover related cell signalling Journal: Oral Diseases Manuscript ID: ODI-02-10-OM-1552.R1 Manuscript Type: Original Manuscript Date Submitted by the 07-Oct-2010 Author: Complete List of Authors: Wehrhan, Falk; University of Erlangen-Nürnberg,
    [Show full text]
  • Efficacy and Safety of Elcatonin in Postmenopausal Women with Osteoporosis: a Systematic Review with Network Meta-Analysis of Randomized Clinical Trials
    Osteoporosis International (2019) 30:1723–1732 https://doi.org/10.1007/s00198-019-04997-6 REVIEW Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials W.-C. Chen1,2 & E.-Y. Lin3 & Y.-N. Kang1,4 Received: 20 November 2018 /Accepted: 21 April 2019 /Published online: 1 May 2019 # International Osteoporosis Foundation and National Osteoporosis Foundation 2019 Abstract Summary The present systematic review aimed to evaluate bone mineral density (BMD) change and complication rates of elcatonin on treating postmenopausal osteoporosis. The result confirmed efficacy of elcatonin and safety in combination thera- pies of elcatonin (C-E). Introduction Postmenopausal osteoporosis is an important issue in global aging trends. One treatment of osteoporosis is elcatonin, a kind of calcitonin. However, it has been challenged for long time because of safety. Many trials investigated on this topic, but they were designed differently. Those designs can be categorized in monotherapy of elcatonin (M-E) and C-E. Unfortunately, no synthesized evidence dealt this topic. Methods This study systematically identified target trials from six important databases and only included randomized controlled trial for synthesis. Two investigators assessed quality of eligible trials using the Cochrane Risk of Bias Tool, and they indepen- dently extracted data. Network meta-analysis performed Peto odds ratio (POR, used for dealing with zero cell) or weighted mean difference (WMD, for continuous data) with 95% confidence intervals (CI) and consistency H. Results Sixteen trials recruiting 2754 women with postmenopausal osteoporosis were included in our study. Elcatonin therapies and non-elcatonin medications had comparable fracture rates and bone mineral density change.
    [Show full text]
  • HELD on 17.03.2012:- the NDAC (Analgesics, Anesthetics
    1. RECOMMENDATIONS OF THE NDAC (ANALGESICS, ANESTHETICS AND RHEUMATOLOGY) HELD ON 17.03.2012:- The NDAC (Analgesics, Anesthetics and Rheumatology) deliberated the proposals on 17.03.2012 and recommended the following:- AGENDA NAME OF DRUG RECOMMENDATIONS NO. New Drugs The firm has requested for 3 indications viz mild to moderate pain, dysmenorrhoea and rheumatoid arthritis and osteoarthritis. Committee recommended that the firm should conduct double blind comparative clinical study of Meclofenamate sodium with diclofenac (100mg/day) in 4 sites distributed geographically in the country. 50% of the sites should be in multispeciality hospitals 1 Meclofenamate which have their own Institutional Ethics Sodium Committee. Ethics Committee approval should be from the same area where the site is located. The firm should submit protocol etc. to the office of DCGI and DCGI may issue approval to the study. Based on the data generated, committee may consider their proposal for the three indications proposed. Committee considered the protocol for conduct of local clinical trial in Indian 2 Flupirtine-D- population. However protocol etc. should be Gluconate forwarded to the members for evaluation and recommendation to DCG(I). Committee recommended for approval of the drug in the country subject to submission of CDTL test report to DCG(I). Phase IV clinical trial should be conducted on 500 patients 3 Apixaban within 2 years. Protocol for the Phase IV trial should be submitted to DCG(I) within 3 months of approval of the drug which can be considered and approved by DCG(I). In view of cardiovascular safety concern, committee recommended for giving 4 Dexmedetomidine permission to conduct the study subject to condition that the study should be conducted in subjects aged 8 years and above.
    [Show full text]
  • We Need Drugs That…
    7/5/2016 Disclosures New Osteoporosis Treatments Mary L. Bouxsein, PhD Advisory Board: Merck, Eli Lilly, Radius Department of Orthopedic Surgery Harvard Medical School, Boston, MA Research funding: Merck, Amgen Consulting fees: Acceleron Pharma, Agnovos What we have today We need drugs that… • Treatments that reduce the risk of vertebral • Maintain or promote bone formation fractures by 50 to 80% • Strengthen cortical bone —> reduce Non‐VFx • Treatments that reduce the risk of non‐vertebral fractures by 20‐25% – Non‐vertebral fracture remain major source of disability • Are convenient for patient • Are cost‐effective % of days of disability due to different • Are safe types of fractures Results from FIT II Cummings et al, JAMA 2006 1 7/5/2016 New treatments, new mechanisms of action Cathepsin K and Bone Resorption • CatK is a lysosomal protease highly expressed in osteoclasts, where it is • Cathepsin K inhibitors released during bone resorption Odanacatib (ODN) • CatK is the major protease responsible for degradation of type I collagen • Anti‐sclerostin antibody Romozosumab • Novel PTH Analogs Abaloparitide (BA‐058) Rodan SB et al. IBMS BoneKey. 2008;5:16–24. Global deletion of Cathepsin K in mice decreases bone resorption but increases bone formation Distal femur Serum CTx WT How can cathepsin K inhibition lead to increased bone formation? WT KO Revisiting the ‘coupled’ process of BFR/BS KO bone remodeling WT KO Pennypacker B. et al., Bone, 2009 2 7/5/2016 Coupling of bone formation & resorption Genetic deletion of CatK in osteoclasts Bone mass Bone resorption OPG “Clastokines” Bone formation RANKL Osteoclast # CON OC CatK KO ) * 2 # Oc MDGFs BFR * (IGF1, TGFß) BFR/TV (%/year) Image courtesy of R.
    [Show full text]
  • Adhesive Preparation
    (19) & (11) EP 2 062 584 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (43) Date of publication: (51) Int Cl.: 27.05.2009 Bulletin 2009/22 A61K 31/663 (2006.01) A61K 9/70 (2006.01) A61K 47/06 (2006.01) A61K 47/08 (2006.01) (2006.01) (2006.01) (21) Application number: 07807007.5 A61K 47/10 A61K 47/14 A61K 47/32 (2006.01) A61P 1/02 (2006.01) (2006.01) (2006.01) (22) Date of filing: 10.09.2007 A61P 3/14 A61P 19/00 A61P 19/02 (2006.01) A61P 19/10 (2006.01) A61P 29/00 (2006.01) A61P 35/00 (2006.01) A61P 35/02 (2006.01) A61P 35/04 (2006.01) (86) International application number: PCT/JP2007/067597 (87) International publication number: WO 2008/032678 (20.03.2008 Gazette 2008/12) (84) Designated Contracting States: • HAYASHI, Noriyuki AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Imizu-shi HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE Toyama 939-0351 (JP) SI SK TR • SAKAI, Yoshiki Designated Extension States: Mishima-gun AL BA HR MK RS Osaka 618-8585 (JP) (30) Priority: 11.09.2006 JP 2006245965 (74) Representative: Keller, Günter et al Lederer & Keller (71) Applicant: Kyukyu Pharmaceutical Co., Ltd. Patentanwälte Tokyo 103-0023 (JP) Prinzregentenstrasse 16 80538 München (DE) (72) Inventors: • YAMAZAKI, Yuuhiro Imizu-shi Toyama 939-0351 (JP) (54) ADHESIVE PREPARATION (57) The present invention provides an adhesive of either of the bisphosphonic acid derivative or the salt, preparation having a plaster layer disposed on a support, a solubilizer for the active ingredient, propylene glycol, a the adhesive preparation comprising at least one active hydrogenated terpene resin, an adhesive base, and a ingredient selected from the group consisting of a bi- softening agent in the plaster layer.
    [Show full text]
  • Targeting Cathepsin K for the Treatment of Osteoporosis – Focus
    Drugs or :he Future 2010, 35(8): 643-,;49 THOMSON Rf.CJTfRS \' (opvtlght ~ lOIO Prous Sd1.?no:•, SA U. <11 it~ lir.f:>nsor!=. At~ right~ r~~Q1~d CCC: 0.377-Lll82/W10 001: 10 1353/~of.2010 35 8 .152~'l'.2 F{E\/!EW J\f<TICLE TARGETING CATHEPSIN K FOR THE TREATMENT OF OSTEOPOROSIS: FOCUS ON ODANACATIB E.M. Lewiecki New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA CONTENTS density (BMD) and bone strength are stable. II bone resorption SummJry .......... ....... .. , . .... ..... • ...... ... .643 exceeds bone formation, as occurs in postmenopausat estrogen· deficient women, there is a net loss of bone over time that may ulti· Introduction ........ ........ • .. .... .. • ..... ..... .. .643 mately result in osteoporosis and increased risk of fractures (1) . Cathepsin K inhibitors .......... .. ...... .. .... ... .... .645 Osteoporosis is a common disease associated with increased Conclusions ....... ....... .. .. .. ...... ....... .648 morbidity, increased mortality and high henlthcare costs due to frac­ Referencr.s .......... ..•. .. .... ... • . ... • .. .. , .. .648 tures (2). Bone resorption requires the attachment of an osteoclast to the bone surface by means of a "sealing zone" in order to create a self· SUMMARY contained compartment between the bone surface and the adjacent Cathepsin K is a lysosomal cysteine protease expressed by osteoclasts ruffled border of the osteoclast (3). The acidic microenvironment that degrades type I collagen during the process of bone remodeling. beneath the osteoclast demineralizes the bone and exposes the Postmenopovsal osteoporosis (PMO) is a disease of excessive bone underlylng matrix, which is then degraded through the action of cys­ tvrnover, wit/1 an imbalance between bone resorption and bone formo - teine proteases (4). Since cathepsin K is the most abundant cysteine tion that covses loss of bone strength and increased risk of fractures.
    [Show full text]
  • Clinical Effects of Switching from Minodronate to Denosumab
    Kobayashi et al. BMC Women's Health (2020) 20:48 https://doi.org/10.1186/s12905-020-00913-x RESEARCH ARTICLE Open Access Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study Masaki Kobayashi, Kenjiro Sawada*, Akihiko Yoshimura, Misa Yamamoto, Aasa Shimizu, Kotaro Shimura, Naoko Komura, Mayuko Miyamoto, Kyoso Ishida and Tadashi Kimura Abstract Background: Denosumab is a major treatment option for patients with postmenopausal osteoporosis; however, the evidence for its use is lacking. Therefore, in this 24-month retrospective study, we aimed to evaluate the effects of switching from minodronate (MIN) to denosumab in these patients. Methods: Patients with postmenopausal osteoporosis either switched from MIN to denosumab (Group 1; n = 32) or continued MIN treatment (Group 2; n = 24). Bone mineral density (BMD) of the lumbar spine (L2–L4) and femoral neck was assessed at baseline and every 6 months for 24 months. Serum bone- specific alkaline phosphatase (BAP) and N-terminal telopeptide were measured at baseline, 12 months, and 24 months. Results: Twenty-nine of the 32 patients (90.6%) in group 1 and all patients (24/24) in group 2 completed the 24-month follow-up. Switching from MIN to denosumab (Group 1) significantly increased lumbar BMD at 12, 18, and 24 months (6.1, 7.4, and 9.6%, respectively) and femoral neck BMD at 12, 18, and 24 months (2.8, 3.2, and 3.4%, respectively), whereas MIN continuous treatment (Group 2) showed no significant difference from baseline. Switching therapy also showed a significant decrease in serum BAP from baseline to 12 and 24 months (− 19.3 and − 26.5%, respectively) and serum NTX from baseline to 12 months (− 13.1%), whereas continuous MIN treatment failed to show any significant differences from baseline.
    [Show full text]
  • 10 Jahre UNIVERSUM INNERE MEDIZIN Liebe
    P.b.b. GZ02Z031655M, Benachrichtigungspostamt 1070 Wien unDie Fachzeitschrift versum der Österreichischen Gesellschaft für Innere Medizin InnereMedizinInnereMedizin Sonderausgabe aus Anlass des 10-jährigen Bestehens von UNIVERSUM INNERE MEDIZIN Österreichische Gesellschaft für Innere Medizin www.oegim.at 1010 Jahre Jahre InnereInnere MedizinMedizin FortschritteFortschritte undund KontroversenKontroversen ausaus derder Jubiläums-PerspektiveJubiläums-Perspektive MedMedia Falls unzustellbar,Falls bitte retour an:Verlag, MEDMEDIA 1.1, Seidengasse 9/Top Wien 1070 Verlags Ges.m.b.H. Fachkurzinformation siehe Seite 68 GRUSSWORT DES HERAUSGEBERS o. Univ.-Prof. Dr. Günter j. Krejs Herausgeber Universum Innere Medizin 10 Jahre UNIVERSUM INNERE MEDIZIN Relevanz und Aktualität zu bieten. Dafür danken wir ganz diese 10 Jahre, die hinter uns liegen, und helfen Sie mit, herzlich allen unseren vielen Autoren. dass UNIVERSUM INNERE MEDIZIN auch in der Zukunft Es ist ein besonderer Anlass und es erfüllt uns mit Freude, In dieser Jubiläumsausgabe haben Sie einen breiten Quer- erfolgreich sein wird. dass wir auf den Erfolg dieser letzten Jahre zurückblicken schnitt dessen, was wir in den verschiedensten Sparten dürfen. Eine große Zahl von Ärzten und Spezialisten aus den publiziert haben. Ich bin sicher, Sie werden diese Ihr verschiedensten Bereichen haben dazu beigetragen, Sie Jubiläumsausgabe mit Vergnügen lesen. Sie kommt auch immer sehr prompt über neueste Entwicklungen und neue- rechtzeitig zur 40. Jahrestagung der Österreichischen ste Diagnostik und Therapie zu informieren. Die kurze Zeit Gesellschaft für Innere Medizin, für die UNIVERSUM INNERE vom Erstellen der Manuskripte bis zum Druck (durch- MEDIZIN ein Eckpfeiler der Publikationen der Gesellschaft schnittlich 6 Wochen) erlaubt es, Information von größter wurde. Autoren und Leser, freuen Sie sich mit uns über o.
    [Show full text]
  • Efficacy of a Cathepsin K Inhibitor in a Preclinical Model for Prevention and Treatment of Breast Cancer Bone Metastasis
    Author Manuscript Published OnlineFirst on September 23, 2014; DOI: 10.1158/1535-7163.MCT-14-0253 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Efficacy of a Cathepsin K Inhibitor in a Preclinical Model for Prevention and Treatment of Breast Cancer Bone Metastasis Le T. Duong1, Gregg A. Wesolowski, Patrick Leung, Renata Oballa*, Maureen Pickarski Merck & Co. Inc., Whitehouse Station, NJ, USA. Running Title: Cathepsin K inhibitor for metastatic bone disease Keywords: Cathepsin K inhibitor, osteoclast, metastatic bone disease, osteolysis, breast cancer. 1Author for correspondence: Le T. Duong, Ph.D. Bone Biology Merck & Co., Inc. 770 Sumneytown Pike West Point, PA 19486, USA Tel. 215-652-7574 Fax: 215-652-4328 E-mail: [email protected] Funding Statement - This study was funded by Merck & Co., Whitehouse Station, NJ, USA Downloaded from mct.aacrjournals.org on September 27, 2021. © 2014 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 23, 2014; DOI: 10.1158/1535-7163.MCT-14-0253 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Cathepsin K inhibitor for metastatic bone disease Le T. Duong Bone Biology Merck & Co., Inc. 770 Sumneytown Pike West Point, PA 19486, USA Tel. 215-652-7574 Fax: 215-652-4328 E-mail: [email protected] Gregg A. Wesolowski Bone Biology Merck & Co., Inc. 770 Sumneytown Pike West Point, PA 19486, USA E-mail: [email protected] Patrick Leung Bone Biology Merck & Co., Inc. 770 Sumneytown Pike West Point, PA 19486, USA E-mail: [email protected] *Renata Oballa Inception Sciences Canada Inc.
    [Show full text]
  • Amgen and UCB Push Forward with Bone-Building Antibody
    April 04, 2012 Amgen and UCB push forward with bone-building antibody Jonathan Gardner Promising mid-stage results for what could be the first bone-building antibody to treat osteoporosis have encouraged two companies that could use a little help from their pipelines to initiate a phase III trial. Amgen the world’s biggest biotech and UCB the Belgian specialty pharma company today announced plans to test AMG 785 (CDP7851) in 5,000 women in a trial that should report in 2015, and show whether the therapy can reduce the incidence of fractures. Introducing an expensive biological into what will be a very genercised market – even Eli Lilly’s bone-building incumbent Forteo will be nearing the end of its market exclusivity by the time the Amgen/UCB antibody can reach prescribing physicians – will be a big ask. Still, Forteo, itself a biological, has been able to carve out blockbuster sales even going up against off-patent drugs by targeting high-risk patients and those intolerant to bisphosphonates, suggesting there is still a place for new treatments. Building bone Bisphosphonates have shown themselves able to improve bone mineral density and reduce the risk of fractures by preventing bone resorption, the process by which mature tissue is removed from the skeleton. By contrast, AMG 785 aims to stimulate bone formation; it does so by inhibiting the action of sclerostin, a protein that inhibits bone formation, on bone morphogenetic proteins. Sclerostin levels are low in patients with sclerosteosis, a disease characterised by excessive bone growth. Likewise, Forteo, or teriparatide, a recombinant form of parathyroid hormone, increases the number and action of bone-building osteoblasts.
    [Show full text]
  • Odanacatib: a Possible New Therapeutic Option for the Treatment of Osteoporosis
    Drug Evaluation Odanacatib: a possible new therapeutic option for the treatment of osteoporosis Cathepsin K is a protease released by osteoclasts, which is involved in the destruction of collagen fibers that form the organic phase of the bone matrix, and plays a key role in bone resorption. Odanacatib is a selective inhibitor of cathepsin K, which blocks bone remodeling by inhibiting resorption. Phase II trials have shown that odanacatib is a potent antiresorptive agent and does not significantly reduce biochemical markers of bone formation during long-term treatment of postmenopausal women. This increases the bone mineral density that is comparable with the most powerful antiresorptive agents. Odanacatib has a generally favorable tolerability and safety profile. Currently, only Phase II studies have been reported and its efficacy in reducing fractures has not been demonstrated. The adverse effects are reversible and disappear after discontinuation. If this antifracture efficacy can be shown, odanacatib could be a safe, efficacious option for the treatment of osteoporosis. KEYWORDS: cathepsin K n odanacatib n osteoclast n osteoporosis José Luis Pérez-Castrillón*1,2, Florentino Pinacho3, Throughout life, bone remodeling maintains the gene that codes for cathepsin K, causing an Marta Ruiz-Mambrilla4 the structure of bone tissue, leading to changes increase in BMD, low stature, cranial deformi- & Antonio Dueñas Laita3 in bone density, shape and strength that allow ties and acroosteolysis of the distal phalanges 1Internal Medicine Department, it to adapt to biomechanical circumstances at [4]. In addition to osteoclasts, osteocytes secrete Rio Hortega University Hospital, Faculty of Medicine, Valladolid, Spain any given time. This remodeling occurs both in cathepsin K, although their function remains 2Institute of Endocrinology & Nutrition cortical bone, which is responsible for load bear- unknown.
    [Show full text]